Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD19 CAR double-negative T cells RJMty19

An off-the-shelf (OTS) cell preparation composed of healthy, donor-derived CD4 and CD8 double-negative T lymphocytes (DNTs) that are transduced with a lentiviral vector expressing a humanized chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR DNTs RJMty19 specifically targets and binds to tumor cells expressing CD19. This induces selective toxicity in tumor cells that express CD19. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. The DNTs contain a high proportion of stem cell-like memory T cells (Tscm).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allo-DNT cells RJMty19
allogeneic anti-CD19 CAR DNT cells RJMty19
allogeneic anti-CD19 CAR-engineered double negative T cells RJMty19
allogeneic DNT cells RJMty19
allogeneic DNTs RJMty19
bi-negative T cells RJMty19
CD19-CAR-DNT cells RJMty19
lentiviral vector-transduced anti-CD19-CAR DNT cells RJMty19
Code name:RJMty 19
RJMty-19
RJMty19
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search